

## IGF-1, IGFBP-3, and cancer risk

Andrew Renehan and colleagues (April 24, p 1346)<sup>1</sup> report the results of a meta-regression analysis of insulin-like growth factor 1 (IGF-1), IGF binding protein 3 (IGFBP-3), and the risk of cancer, and show a modest positive correlation between IGF-1 or IGFBP-3 and common cancers. However, Renehan and colleagues do not mention the ongoing discussion about IGF-1 and IGFBP-3 and the risk of acute leukaemia.

Diverse studies have reported on acute lymphoblastic and

acute myeloid leukaemia (M1). After initial diagnosis in 1999, followed by intensive chemotherapy, she is still in remission.

In summary, although these data might not yet reach significance, the possibility of a positive correlation between IGF-1 concentrations and acute leukaemia should be mentioned in meta-analyses such as the one by Renehan and colleagues.

quantities and the inherent instability of IGF-1 in the blood compared with those of IGFBP-3 are likely to hinder documentation of an underlying positive association between IGF-1 and acute leukaemia.

In our outpatient clinic, we regularly see a 30-year-old female patient with acromegaly and initially highly increased (>99th percentile) IGF-1 concentrations, who also developed

- 4 Eshet R, Silbergeld A, Zaizov R, et al. Decreased insulin-like growth factor-I receptor sites on circulating mononuclear cells from children with acute leukemia. *Pediatr Hematol Oncol* 2000; **17**: 253-60.
- 5 Petridou E, Dessypris N, Spanos E, et al. Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia. *Int J Cancer* 1999; **80**: 494-96.

The Lancet is a weekly subscription journal. For further information on how to subscribe please contact our Subscription Department  
Tel: +44 (0) 20 7611 4102 Fax: +44 (0) 20 7611 4479  
North America Tel: +1 (800) 462 6198 Fax: +1 (212) 633 3974